Firefly white paper shows BNA platform boosts MDD treatment compliance 15%, cuts med switches >50%

FIREFLY NEUROSCIENCE, INC.

Analysis of 2,253 patients at a U.S. psychiatric clinic using Firefly’s BNA Platform.
MDD treatment adherence rose 15%; need for antidepressant switches fell >50%.
Patients with MDD, GAD, ADHD saw >2x improvement in general functioning.
Antidepressant response rates increased 10%; non-responder rate fell 17%.
Results support Firefly’s planned merger with WaveDancer (WAVD); shareholder vote set for March 14.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.